Moderna, a US pharmaceutical company, has announced that it will apply to the Food and Drug Administration (FDA) for emergency use authorisation for its Covid-19 vaccine in children under the age of six. Moderna said in a statement on Wednesday that it will submit the request to the FDA, the European Medicines Agency, and other global agencies "in the next weeks," report said.
The application was based on results from studies of the Covid-19 vaccine, also known as mRNA-1273, in children aged 6 months to under 2 years and 2 years to under 6 years.
Moderna said, the interim study revealed a substantial neutralising antibody response in both age groups after a 25 microgram two-dose primary series of mRNA-1273, as well as a favourable safety profile. It said, the vaccine efficacy was 43.7 percent in children aged 6 months to 2 years, and 37.5 percent in children aged 2 to under 6 years.
COVID Roundup: India reports 1,938 new cases, 67 deaths in 24-hrs
Study finds Pioneering technique could unlock targeted treatments for cancer
